text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 190791-29-8 | Product Number: L0336

Lasofoxifene Tartrate


Purity: >98.0%(HPLC)
Synonyms:
  • (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol Tartrate
  • Oporia
Documents:
10MG
₹4,400
Contact Us Contact Us 18  
50MG
₹14,400
Contact Us Contact Us ≥20 

*Upon orders receipt, Hyderabad stocks will be dispatched on the same day & Chennai stocks will be dispatched in 3-6 working days.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*Change currency to place order in USD.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.


Product Number L0336
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__2__8H__3__1NO__2·C__4H__6O__6 = 563.65  
Physical State (20 deg.C) Solid
Storage Temperature 0-10°C
Store Under Inert Gas Store under inert gas
Condition to Avoid Air Sensitive,Hygroscopic,Heat Sensitive
CAS RN 190791-29-8
Reaxys Registry Number 14771789
MDL Number

MFCD30207839

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Properties (reference)
Melting Point 185 °C(dec.)
GHS
Related Laws:
RTECS# QK4252964
Transport Information:
Application
Lasofoxifene tartrate: A Third-Generation, Non-Steroidal Selective Estrogen Receptor Modulator (SERM)

Lasofoxifene tartrate (CP-336156) is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). SERMs have the ability to provide mixed functional estrogen receptor (ER) agonist or antagonist activity, depending on the target tissue. Lasofoxifene has a remarkably improved oral bioavailability with respect to other SERMs, selectively binds to both ERα and ERβ with high affinity, and acts as a tissue selective estrogen antagonist or agonist.1-3) It has been reported that lasofoxifene prevents estrogen deficiency-induced bone loss, inhibits breast tumor formation and reduces serum cholesterol. In clinical, lasofoxifene tartrate has been used for the treatment of osteoporosis4) and breast cancer.5,6) (The product is for research purpose only.)

References


Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents